Dr. Lyon on a phase 2 study of in-home treatment for NMIBC
“The primary outcome will be feasibility of in-home treatments,” says Timothy D. Lyon, MD, FACS.
In this video, Timothy D. Lyon, MD, FACS, discusses future work building off the study, “Patient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer,” for which he served as the senior author. Lyon is an associate professor of urology at Mayo Clinic in Jacksonville, Florida.
Video Transcript:
On the basis of these findings, we've decided to move ahead with a phase 2 trial, specifically looking at the ability to deliver in-home intravesical therapies for patients with non-muscle invasive bladder cancer. The primary outcome will be feasibility of in-home treatments, with key secondary outcomes being patient preference for in-home vs in-clinic installations, as well as likelihood of recommending to other bladder cancer patients. Of course, we'll also be collecting safety data, patient-reported outcomes and quality of life data during the process.
This transcription has been edited for clarity.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
